Optimizing treatment of the partially platinum-sensitive ovarian cancer patient

Future Oncology

Volumn 9, Issue 12 SUPPL., 2013, Pages 19-23

  Colombo, Nicoletta ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

ovarian cancer; partially platinum sensitive; pegylated liposomal doxorubicin; platinum free interval; second line chemotherapy; trabectedin

Indexed keywords

DOXORUBICIN; PLATINUM; TRABECTEDIN;

ALOPECIA; CANCER RECURRENCE; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG HYPERSENSITIVITY; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POLYNEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DIOXOLES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PLATINUM; POLYETHYLENE GLYCOLS; TETRAHYDROISOQUINOLINES;

EID: 84887908296     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.206     Document Type: Conference Paper

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D., Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893-2917 (2010).
2. Rakowski JA, Ahmad S, Holloway RW. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev. Anticancer Ther. 12, 31-40 (2012).
3. Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21, 771-775 (2011).
4. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 Phase III randomized trial. Ann. Oncol. 22, 39-48 (2011).
5. Sehouli J, Alfaro V, González-Martín A. Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives. Ann. Oncol. 23, 556-562 (2012).
6. Poveda A. Trabectedin: changing paradigms in the treatment of relapsed ovarian cancer. Presented at: the IGCS 13th Biennial Meeting. Prague, Czech Republic, 23 October 2010.
7. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J. Clin. Oncol. 28, 3107-3114 (2010).
8. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival ana lysis. Eur. J. Cancer 48, 2361-2368 (2012).
9. Horowitz NS, Hua J, Gibb R.K., Mutch DG, Herzog TJ. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Gynecol. Oncol. 94, 67-73 (2004). (Pubitemid 38950500)
10. Kavanagh J, Tresukosol D, Edwards C et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J. Clin. Oncol. 13, 1584-1588 (1995).
11. Bookman MA. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy. Oncologist 4, 87-94 (1999). (Pubitemid 29202993)
12. See HT, Freedman RS, Kudelka AP et al. Retrospective review: re-treatment of patients with ovarian cancer with carboplatin after platinum resistance. Int. J. Gynecol. Cancer 15, 209-216 (2005). (Pubitemid 40396954)
13. Colombo N. Efficacy of trabectedin in platinum-sensitive-relapsed ovarian cancer: new data from the randomized OVA-301 study. Int. J. Gynecol. Cancer 21(Suppl. 1), S12-S16 (2011).
14. Kaye SB, Colombo N, Monk BJ et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann. Oncol. 22, 49-58 (2011).
15. Vergote I, Vermorken J, Pujade-Lauraine E et al. Safety ana lysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older. Presented at: the ECCO-ESMO. Berlin, Germany, 23 September 2009.
16. Krasner CN, Poveda A, Herzog TJ et al. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecol. Oncol. 127, 161-167 (2012).
17. Vermorken JB, Kelley J, Provencher D et al. Patient-reported outcomes in patients with relapsed, platinum-sensitive ovarian cancer (ROC): results from a large randomized Phase III trial. Int. J. Gynecol. Cancer 20(Suppl. 2), Abstract 00458 (2010).
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. www.nccn.com
19. Yondelis H-773-II-08 Assessment Report. EMA (2010). www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Assessment-Report-Variation/human/000773/ WC500059175.pdf